Because of the toxicity of the two drugs, however, cancer patients undergoing chemotherapy often suffer debilitating nausea. Hundreds of millions of dollars invested toward reducing such side effects have yielded positive results. Pharmaceutical firms such as Bristol Myers Squibb actively market their chemotherapeutic drug, Paraplatin, a carboplatin for injection that promises better-tolerated platinum therapy. Alongside of advances being made in genetically engineered cancer treatments, progress and research continues to hinge upon platinum-based drug usage in the field. A review of an industry periodical, Oncology Times , demonstrates the extent of such research for example with 7 out of 10 treatment protocol studies utilizing platinum-based drug for small cell cancers.
Major initiatives are afoot in the jewelry industry.
Moet Hennessy Louis Vuitton, the French luxury group, announced the formation of a joint venture to sell De Beers branded diamond jewelry. De Beers will transfer worldwide rights to LVMH, which will use the De Beers brand for luxury goods. Subject to EU regulatory approval, the business is expected to being in the next 12-18 months with a small number of flagship retail stores located in the world's most prestigious cities.